What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?
作者信息
Sharma Surendra K, Dheda Keertan
机构信息
Department of Molecular Medicine, Jamia Hamdard Institute of Molecular Medicine, Jamia Hamdard (Deemed-to-be-University), New Delhi; Departments of General Medicine & Respiratory Medicine, Jawaharlal Nehru Medical College (JNMC), Datta Meghe Institute of Medical Science, Wardha, India.
Department of Medicine & UCT Lung Institute, Division of Pulmonology, Centre for Lung Infection & Immunity, University of Cape Town, Cape Town, South Africa; Department of Immunology & Infection, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
出版信息
Indian J Med Res. 2019 Mar;149(3):309-312. doi: 10.4103/ijmr.IJMR_579_19.
Abstract
摘要
相似文献
1
What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?
Indian J Med Res. 2019 Mar;149(3):309-312. doi: 10.4103/ijmr.IJMR_579_19.
2
Drug-resistant tuberculosis: reality and potential threat.
Int J Tuberc Lung Dis. 2010 Mar;14(3):255-8.
3
Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia.
Int J Tuberc Lung Dis. 2010 Oct;14(10):1259-65.
4
Multidrug-resistant/extensively drug-resistant tuberculosis in Greece: predominance of Mycobacterium tuberculosis genotypes endemic in the Former Soviet Union countries.
Clin Microbiol Infect. 2017 Dec;23(12):1002-1004. doi: 10.1016/j.cmi.2017.07.002. Epub 2017 Jul 8.
5
Resistance to anti-tuberculosis medications in the Horn of Africa.
Int J Tuberc Lung Dis. 2011 Mar;15(3):414-6.
6
Practical considerations to implement the shorter regimen to MDR-TB patients in China.
Clin Microbiol Infect. 2018 Oct;24(10):1035-1036. doi: 10.1016/j.cmi.2018.04.026. Epub 2018 May 3.
7
Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa.
Emerg Infect Dis. 2011 Mar;17(3):510-3. doi: 10.3201/eid1703.101363.
8
Management of multidrug resistant tuberculosis.
Semin Respir Crit Care Med. 2013 Feb;34(1):44-59. doi: 10.1055/s-0032-1333546. Epub 2013 Mar 4.
9
State of the Art series on drug-resistant tuberculosis: it's time to protect fluoroquinolones.
Int J Tuberc Lung Dis. 2009 Nov;13(11):1319.
10
Challenges and Outlooks in Multi-drug Resistant Tuberculosis.
Arch Bronconeumol. 2017 Aug;53(8):417-418. doi: 10.1016/j.arbres.2017.01.018. Epub 2017 Mar 14.
引用本文的文献
1
Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar;398(3):2127-2150. doi: 10.1007/s00210-024-03466-0. Epub 2024 Oct 8.
2
Audit of essential medicine listing and registration status of medicines on standard treatment guidelines in Kenya, Tanzania and Uganda: Case study of malaria, tuberculosis, hypertension and type 2 diabetes mellitus.
JRSM Open. 2024 Mar 29;15(3):20542704241232814. doi: 10.1177/20542704241232814. eCollection 2024 Mar.
3
mHealth application for improving treatment outcomes for patients with multidrug-resistant tuberculosis in Vietnam: an economic evaluation protocol for the V-SMART trial.
BMJ Open. 2023 Dec 11;13(12):e076778. doi: 10.1136/bmjopen-2023-076778.
4
Computational Insight into Substrate-Induced Conformational Changes in Methionyl-tRNA Synthetase of Mycobacterium Tuberculosis.
Protein J. 2023 Oct;42(5):533-546. doi: 10.1007/s10930-023-10135-3. Epub 2023 Jul 4.
5
Oral regimen for multi-drug-resistant TB can promote patient-centred and community-based treatment.
J Family Med Prim Care. 2021 Dec;10(12):4607-4608. doi: 10.4103/jfmpc.jfmpc_2502_20. Epub 2021 Dec 27.
6
Does optimized adherence support improve treatment outcomes in RR / MDR-TB patients on 18-20 months regimen in Tbilisi, Georgia?
J Infect Dev Ctries. 2021 Sep 29;15(9.1):34S-42S. doi: 10.3855/jidc.13783.
7
Development of a nomogram for predicting treatment default under facility-based directly observed therapy short-course in a region with a high tuberculosis burden.
Ther Adv Infect Dis. 2021 Jul 29;8:20499361211034066. doi: 10.1177/20499361211034066. eCollection 2021 Jan-Dec.
8
Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.
Pharmaceuticals (Basel). 2021 May 13;14(5):461. doi: 10.3390/ph14050461.
9
Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications.
Epidemiol Health. 2021;43:e2021022. doi: 10.4178/epih.e2021022. Epub 2021 Apr 7.
10
Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults.
BMJ Open. 2021 Mar 2;11(3):e044687. doi: 10.1136/bmjopen-2020-044687.
本文引用的文献
1
Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen.
Int J Infect Dis. 2019 Aug;85:74-79. doi: 10.1016/j.ijid.2019.04.028. Epub 2019 May 14.
2
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.
3
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7.
4
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
5
Drug-resistant tuberculosis: is India ready for the challenge?
BMJ Glob Health. 2018 Aug 10;3(4):e000971. doi: 10.1136/bmjgh-2018-000971. eCollection 2018.
6
Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):677-689. doi: 10.1080/14737167.2018.1507821. Epub 2018 Aug 23.
7
The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?
Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1114-1126. doi: 10.5588/ijtld.17.0468.
8
Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
Eur Respir J. 2017 Jul 27;50(1). doi: 10.1183/13993003.00061-2017. Print 2017 Jul.
9
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.
Lancet Respir Med. 2017 Mar 15. doi: 10.1016/S2213-2600(17)30079-6.
10
Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study.
Lancet. 2014 Apr 5;383(9924):1230-9. doi: 10.1016/S0140-6736(13)62675-6. Epub 2014 Jan 17.
Zotero 插件